Author:
Bezrodnyi B. G.,Kolosovich I. V.,Slobodjanyk V. P.,Petrenko O. M.,Filatov M. S.
Abstract
Summary. The development of new technological solutions for palliative surgical treatment of patients with unresectable pancreatic cancer is relevant because the frequency of postoperative complications in such patients reaches 25 % and mortality — 20 %.
Objective. Improve the diagnosis and immediate results of palliative surgical treatment of patients with unresectable pancreatic cancer complicated by mechanical jaundice and duodenal obstruction.
Materials and methods. A comparative analysis of the results of surgical treatment of two groups of patients (11 patients in the first and 27 in the second) for unresectable pancreatic cancer complicated by mechanical jaundice and gastric evacuation disorders due to duodenal obstruction. Patients of group I performed only biliodigestive shunting by open surgery. Patients in group II obstruction of the bile ducts and duodenum was removed by endoscopic stenting of the biliary system and duodenum with nitinol stents.
Results. It is proved that endoscopic stenting of the biliary system and duodenal obstruction by nitinol stents, compared with open surgery, is accompanied by a lower frequency of postoperative complications (72.7 % vs. 22.2 %, p < 0.05), mortality (27.3 % vs. 0 %, p < 0.001) and reduction of hospital stay (from (24.3 ± 3.74) to (8.7 ± 0.91) days, p <0.001).
Conclusions. The operation of choice of palliative surgical treatment of patients with unresectable pancreatic cancer complicated by mechanical jaundice and evacuation disorders from the stomach, with a high risk of surgery (ASA III), is to perform endoscopic transpapillary stenting of the bile ducts and duodenum.
Publisher
Institute of General and Emergency Surgery Named after V.T. Zaitsev NAMS of Ukraine
Subject
Rehabilitation,Physical Therapy, Sports Therapy and Rehabilitation,General Medicine
Reference8 articles.
1. The pancreas: an integrated textbook of basic science, medicine, and surgery. Edited by Hans Beger G, Andrew Warshaw L, Ralph Hruban H, Markus Büchler W, Markus Lerch M, John Neoptolemos P, et al. Third Edition, p. 1173.
2. Neoptolemos JP, Urrutia R, Abbruzzese JL, Bchler MW. Pancreatic Cancer. Second Edition /Springer, 2019. 1661 p.
3. Cancer Statistics, 2020, CA Cancer J Clin 2020;70:7- 30./ 2020 American Cancer Society. / DOI: 10.3322/ caac.21590.
4. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ducreux M, Sa Cuhna A, Caramella C, et al. Ann Oncol 2015; 26(suppl 5): v56-v68./ Doi:10.1093/annonc/mdv295.
5. NCCN, Clinical Practice Guidelines In Oncology, Pancreatic Adenocarcinoma, Version 2.2021. Journal of the National Comprehensive Cancer Network, Volume 19, Issue 4, Pancreatic Adenocarcinoma, Version 2.2021. DOI: 10.6004/jnccn.2021.0017.